Lecanemab-irmb Approved for Alzheimer Disease
On January 6, 2023, the FDA granted lecanemab-irmb (Leqembi) accelerated approval for treating mild cognitive impairment and mild dementia in patients with Alzheimer disease.
Quizartinib Approved for Newly Diagnosed AML in Patients with ITD
Overall median survival was higher in participants taking quizartinib, according to results from QuANTUM-First trial.
First-in-Class Treatment for Obstructive Hypertrophic Cardiomyopathy Is Approved by FDA
Mavacamten improves functional capacity and symptoms in adults with New York Heart Association class II-III obstructive HCM.